Harvard Health Letter

Has the new sexual desire drug panned out?

During the initial months of availability for flibanserin (Addyi), the first medication for sexual desire disorders, there was not a big demand for the drug, possibly because of a steep price tag and severe potential side effects.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In